|
| 36451039 | Experimental in vitro, ex vivo and in vivo models in prostate cancer research. | Nat Rev Urol | 2023 |
| 37546702 | The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. | Cancer Res Commun | 2023 |
| 36982215 | TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC. | Int J Mol Sci | 2023 |
| 35050902 | Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. | JCI Insight | 2022 |
| 35725938 | Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker. | Urol Oncol | 2022 |
| 35454801 | Histone Demethylase KDM5C Drives Prostate Cancer Progression by Promoting EMT. | Cancers (Basel) | 2022 |
| 35512686 | Targeting cyclin-dependent kinase 7-association between CDK7 and pMED1 expression in prostate cancer tissue. | Carcinogenesis | 2022 |
| 36361816 | The Gene Expression Landscape of Prostate Cancer BM Reveals Close Interaction with the Bone Microenvironment. | Int J Mol Sci | 2022 |
| 35109899 | Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. | J Exp Clin Cancer Res | 2022 |
| 34314763 | CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia. | Hum Pathol | 2021 |
| 34529723 | Cracking it - successful mRNA extraction for digital gene expression analysis from decalcified, formalin-fixed and paraffin-embedded bone tissue. | PLoS One | 2021 |
| 34692726 | Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples. | Front Med (Lausanne) | 2021 |
| 34487169 | Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. | Carcinogenesis | 2021 |
| 30941561 | The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature. | World J Urol | 2020 |
| 32016505 | [Reports of prostate needle biopsies-what pathologists provide and urologists want]. | Urologe A | 2020 |
| 32745892 | International real-world study of DLL3 expression in patients with small cell lung cancer. | Lung Cancer | 2020 |
| 31271443 | Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer. | Int J Cancer | 2020 |
| 30894499 | Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. | Sci Transl Med | 2019 |
| 30232224 | A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. | Clin Cancer Res | 2019 |
| 31178279 | TRIM24 as an independent prognostic biomarker for prostate cancer. | Urol Oncol | 2019 |
| 31628024 | DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature. | EBioMedicine | 2019 |
| 31592503 | Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. | JCO Precis Oncol | 2019 |
| 29266381 | Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. | Cancer | 2018 |
| 29921838 | Patient derived organoids to model rare prostate cancer phenotypes. | Nat Commun | 2018 |
| 30619757 | Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. | Front Oncol | 2018 |
| 29425237 | Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas. | PLoS One | 2018 |
| 29429804 | Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. | Eur Urol | 2018 |
| 27939865 | PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. | J Mol Diagn | 2017 |
| 28331002 | Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. | Cancer Discov | 2017 |
| 28292441 | SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. | Cancer Cell | 2017 |
| 28373416 | On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study. | Anticancer Res | 2017 |
| 28174607 | <i>PITX3</i> DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma. | Clin Epigenetics | 2017 |
| 29333526 | Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. | JCO Precis Oncol | 2017 |
| 28617833 | Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma. | PLoS One | 2017 |
| 28864460 | A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. | Cold Spring Harb Mol Case Stud | 2017 |
| 27035919 | Primary Urethral Plasmacytoma Treated with High-Dose-Rate Brachytherapy: A Case Report. | Urol Int | 2016 |
| 26257066 | PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. | Oncogene | 2016 |
| 27669229 | The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. | Int J Mol Sci | 2016 |
| 27835597 | PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. | Oncotarget | 2016 |
| 27689475 | CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. | Epigenetics | 2016 |
| 27919941 | Ectopic Myoglobin Expression Is Associated with a Favourable Outcome in Head and Neck Squamous Cell Carcinoma Patients. | Anticancer Res | 2016 |
| 27716615 | PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma. | Oncotarget | 2016 |
| 27708722 | <i>PITX3</i> promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. | Clin Epigenetics | 2016 |
| 27462860 | CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients. | Oncotarget | 2016 |
| 25684637 | Glutathione S-transferase-pi protein expression in prostate cancer--not always a useful diagnostic tool. | Histopathology | 2015 |
| 26692530 | Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. | Transl Oncol | 2015 |
| 25850754 | Immunostaining of â¿¿Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast. | Virchows Arch | 2015 |
| 24699908 | Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine. | PLoS One | 2014 |
| 25046199 | Histopathological screening for prostate carcinoma: is a benign biopsy a negative biopsy? | APMIS | 2014 |
| 25172328 | Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia. | Virchows Arch | 2014 |